本 公 告 乃 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，於2026年1月5日，澳 洲Therapeutic Goods Administration（治 療 用 品 管 理 局）（「治療用品局」）已 受 理 評 核 本 公 司 就 其 用 於 治 療 兒 童 近 視 加 深 的 硫 酸 阿 托 品 滴 眼 液（0.01%劑 量，產 品 代 碼：NVK002）提 出 的 註 冊 申 請。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Zhaoke Ophthalmology Limited （於英屬處女群島註冊成立並於開曼群島存續的有限公司） 兆科眼科有限公司 （股份代號：6622） 澳 洲THERAPEUTIC GOODS ADMINISTRATION（治 療 用 品 管 理 局） 受理評核 硫酸阿托品滴 ...

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06622 | 說明 | 兆科眼科有限公司 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,600,000,000,000 USD | | 0.00000025 | USD | | 400,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,600,000,000,000 USD | | 0.00000025 | USD | | 400,000 | 本月底法定/註冊股本總額： USD 400,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 兆科眼科有限公司 呈交日期: 2026年1月2日 I. 法定/註 ...

Core Viewpoint - The "Annual Excellence IR Team (Small and Medium Market Capitalization)" award recognizes outstanding investor relations (IR) teams of listed companies for their significant contributions to industry transformation and development [4]. Group 1: Award Announcement - The "Annual Excellence IR Team (Small and Medium Market Capitalization)" award was presented during the "Technology Empowerment · Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1]. - Ten companies were awarded the "Annual Excellence IR Team (Small and Medium Market Capitalization)" award, including Beikang Medical-B (02170.HK), Gushengtang (02273.HK), Huitongda Network (09878.HK), Jinxin Fertility (01951.HK), Kunbo Medical-B (02216.HK), Lianlian Digital (02598.HK), Qingsi Games (06633.HK), TCL Electronics (01070.HK), Yaxin Technology (01675.HK), and Zhaoke Ophthalmology-B (06622.HK) [1]. Group 2: Evaluation Criteria - The award evaluation focused on the construction of communication channels between IR teams and investors, emphasizing the importance of long-term perspectives on companies' overall performance [4]. - The selection process involved quantitative data analysis and expert review to determine the final results [4]. Group 3: Broader Context - Gelonghui aims to create a reference value ranking of listed companies and unicorns in the investment community, covering all listed companies on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4].

Core Viewpoint - The company has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] Group 1: Partnership Details - The agreement grants Dongshenghua Pharmaceutical exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF [1] Group 2: Regulatory Milestones - In June 2025, Tenpoint Therapeutics, Ltd., the developer of BRIMOCHOL™ PF, announced that the FDA has accepted the new drug application for the product [1] - The FDA has set a review deadline for BRIMOCHOL™ PF under the Prescription Drug User Fee Act (PDUFA) for January 28, 2026 [1]

Core Viewpoint - The company Zhaoke Ophthalmology-B (06622.HK) has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] Group 1: Partnership Details - Zhaoke grants Dongshenghua exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF [1] Group 2: Regulatory Milestones - In June 2025, Tenpoint Therapeutics, Ltd., the developer of BRIMOCHOL™ PF, announced that the FDA has accepted the new drug application for the product [1] - The FDA has set a Prescription Drug User Fee Act (PDUFA) review deadline for BRIMOCHOL™ PF on January 28, 2026 [1]

Core Viewpoint - The company, Zhaoke Ophthalmology-B (06622.HK), has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] Group 1: Partnership Details - Zhaoke grants Dongshenghua exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF [1] - Dongshenghua specializes in chronic diseases and precision medicine, providing safe and accessible healthcare solutions [1] Group 2: Regulatory Updates - In June 2025, Tenpoint Therapeutics, the developer of BRIMOCHOL™ PF, announced that the U.S. FDA has accepted the new drug application for the product [1] - The FDA has set a review deadline for the Prescription Drug User Fee Act (PDUFA) for BRIMOCHOL™ PF on January 28, 2026 [1]

Group 1 - The core viewpoint of the article is that Zhaoke Ophthalmology-B (06622) has entered into a strategic partnership with Dongshenghua Pharmaceutical to jointly advance the clinical introduction and future commercialization of BRIMOCHOL PF in Taiwan [1] - Under the agreement, Zhaoke grants Dongshenghua exclusive distributor rights for the registration, importation, promotion, distribution, marketing, and sales of BRIMOCHOL PF in Taiwan [1] - The developer of BRIMOCHOL PF, Tenpoint Therapeutics, Ltd., announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026, under the Prescription Drug User Fee Act (PDUFA) [1]

Core Viewpoint - The company has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL PF in Taiwan [1] Group 1: Partnership Details - The agreement grants Dongshenghua Pharmaceutical exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL PF [1] Group 2: Product Development and Regulatory Status - Tenpoint Therapeutics, the developer of BRIMOCHOL PF, announced that the FDA has accepted the new drug application for the product, with a Prescription Drug User Fee Act (PDUFA) review deadline set for January 28, 2026 [1]

Core Viewpoint - The company Zhaoke Ophthalmology-B (06622.HK) has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] Group 1: Partnership and Distribution Rights - Zhaoke grants Dongshenghua Pharmaceutical exclusive distributor rights for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF in Taiwan [1] Group 2: Regulatory Developments - In June 2025, Tenpoint Therapeutics, Ltd., the developer of BRIMOCHOL™ PF, announced that the U.S. FDA has accepted the new drug application for the product [1] - The FDA has set a Prescription Drug User Fee Act (PDUFA) review deadline for BRIMOCHOL™ PF on January 28, 2026 [1]

Group 1 - The company Zhaoke Ophthalmology-B (06622) has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] - Dongshenghua Pharmaceutical specializes in chronic diseases and precision medicine, providing safe and accessible healthcare solutions [1] - Under the agreement, Zhaoke grants Dongshenghua exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sales of BRIMOCHOL™ PF [1] Group 2 - By June 2025, Tenpoint Therapeutics, Ltd., a partner of Zhaoke and developer of BRIMOCHOL™ PF, announced that the FDA has accepted the new drug application for the product [1] - The FDA has set a review deadline for BRIMOCHOL™ PF under the Prescription Drug User Fee Act (PDUFA) for January 28, 2026 [1]